Europe Sexual Transmitted Infections (STI) Diagnostics Market: By Disease Type (Chlamydia and Gonorrhea, Trichomoniasis and Mycobacterium Genitalis, Syphilis, Vulvovaginal Candidiasis, Bacterial Vaginosis, Group B Streptococcus, and Herpes Simplex Virus), By Diagnostic Test Type (Cultural Test and PCR Test), By End User (Public and Private), and Country

Europe Sexual Transmitted Infections (STI) Diagnostics Market size was valued at US$ 306.2 million in 2023 and grew at 3.9 % CAGR over the historical years (2019 - 2023). The market is projected to reach US$ 375.4 million by 2030 at a CAGR of 3.1%.  In Europe, the market is driven by some key factors which are rising STD rates, increased awareness, technological advancements, increased population with multiple casual sex partners, and government initiatives in addition to these, it is available for free tests, and the availability of test kits is driving the growth of the market. Across Europe, rates for STDs like Chlamydia, Gonorrhea, and others have been steadily increasing, particularly among young adults. This rise in infections is prompting a surge in demand for diagnostic tests.

Chlamydia and Gonorrhea are the most commonly screened diseases in the European region, followed by TV and MG. The total number of PCR and culture tests estimated volume in 2023 is 38.8 and 5.7 million respectively, in public and private labs in the Europe region approximately 60% of the rest are done in the public labs and 40% are done in private labs. In Europe, most laboratories rely on in-house laboratory-developed tests (LDTs) to diagnose STDs. However, new EU regulations will decrease the dependence on LDTs and promote the use of commercial kits for diagnosis, which could be seen as a potential opportunity for STD diagnostic kits. In terms of value. Multiplex testing, home testing kits, and digital health integration are opportunities in the STD diagnostics market.  Focus on point-of-care testing,  self-sampling techniques, automation, and high-throughput testing are the trends in the STD diagnostics market.  Stigma, reimbursement policies, and data privacy concerns are the constraints in the European region. By understanding these drivers, constraints, opportunities, and trends, stakeholders in the European STD diagnostics market can strategize for future growth and make a positive contribution to public health efforts in the region.

Key Developments:

• In June 2021, Bio-Rad Laboratories, Inc. and Seegene Inc. entered into a collaboration to produce molecular diagnostic products for infectious diseases. As part of this collaboration, Seegene began providing diagnostic tests that are compatible with Bio-Rad’s LFX960x Real-Time PCR System.
• In December 2020, Stilla Technologies, a leading European provider of pioneering solutions for high-precision genetic analyses, launched a dedicated digital PCR MIX reagent line for optimal performance with Crystal Digital PCR.